Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group-Reference-Cited by-同舟云学术

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group

Published:2019-06-14 Issue:9 Volume:30 Page:1855-1864
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Bilezikian J.P.,Lin C.J.F.,Brown J.P.,Wang A.T.,Yin X.,Ebeling P.R.,Fahrleitner-Pammer A.,Franek E.,Gilchrist N.,Miller P.D.,Simon J.A.,Valter I.,Zerbini C.A.F.,Libanati C.,Chines A.

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s00198-019-05020-8.pdf

Reference36 articles.

1. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733. https://doi.org/10.1007/s00198-006-0172-4

2. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM (2005) Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 20(2):185–194. https://doi.org/10.1359/JBMR.041007

3. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(10):1108–1112. https://doi.org/10.1001/archinte.164.10.1108